Current and Emerging Treatments for Transthyretin Amyloid Cardiomyopathy
Ahmad Masri, MD, MS
Shared Decision-Making in Transthyretin Amyloid Cardiomyopathy Care
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
Amy Mottl, MD, MPH
Prof. Christoph Wanner
ECG Markers as Predictors of Adverse Outcomes in COPD: Insights from the IMPACT Trial
Raymond Wade, MD
From Risk to Results: Cases in ASCVD Prevention and Treatment
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Rishi Wadhera, MD, MPP, Mphil
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
Riccardo Maria Inciardi, MD, PhD
Where Does This Patient Land? Making Sense of Risk and LDL-C Goals
The Dose Matters: Optimizing Statin Intensity in ASCVD Management
Expanding Access: Alternative Models for Delivering Lipid-Lowering Therapy
When and Why to Use CAC Scoring
Statins and Safety: What the Data Say About Dementia, Cancer, and More
Closing the Loop: Practical Strategies for Timely Lipid Panel Follow-Up
Target in Sight: Escalating Therapy to Reach LDL-C Goals
Personalizing LDL-C Treatment—Novel Options That Align With Patient Preferences
Unmasking Hidden Risk: The Role of Lp(a) in Cardiovascular Risk Assessment
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Cardiology Academy… but how about a more personalized experience?
Press cancel to remain on Global Cardiology Academy. Press the link below or the continue button to keep going.